Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L)
MATCH Treatment Subprotocol Z1L: BVD-523FB (Ulixertinib) in Patients With Tumors With BRAF Fusions, or With Non-V600E, Non-V600K BRAF Mutations
Sponsor: National Cancer Institute (NCI)
A PHASE2 clinical study on Advanced Lymphoma and Advanced Malignant Solid Neoplasm, this trial is ongoing. The trial is conducted by National Cancer Institute (NCI) and has accumulated 9 data snapshots since 2019. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
9 versions recorded-
Dec 2025 — Present [monthly]
Active Not Recruiting PHASE2
-
Oct 2025 — Dec 2025 [monthly]
Active Not Recruiting PHASE2
-
Jun 2025 — Oct 2025 [monthly]
Active Not Recruiting PHASE2
-
May 2025 — Jun 2025 [monthly]
Active Not Recruiting PHASE2
-
Mar 2025 — May 2025 [monthly]
Active Not Recruiting PHASE2
▶ Show 4 earlier versions
-
Dec 2024 — Mar 2025 [monthly]
Active Not Recruiting PHASE2
-
Sep 2024 — Dec 2024 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
First recorded
Jul 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .